Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: the remaining session of the week

October 26, 2018 8:10am

This sector is more concerned with volatility than fundamentals

Which is on-going and not gone – ready for another encore?

Pre-open indications: 2 SELL

I post about “indication intelligence” devoting my time to collection and analysis of information in the perception of sector vulnerabilities and strengths – it’s more than opinion, some facts in evidence need to be recognized!

Stock index futures are plunging yet again

Dow futures are DOWN -0.86% (-215 points) and NASDAQ futures are DOWN -2.08% (-144 points)

U.S. stock futures pointed to a significantly lower open

European stocks tumbled, tracking a decline in U.S. stocks futures

Asia markets were mostly down as major indexes see-sawed between gains and losses.

Data docket: U.S. third-quarter gross domestic product (GDP) data is due today at 8:30 a.m. ET, while consumer sentiment figures will come in at 10 a.m. ET.

Today’s indications:

The iShares Nasdaq Biotechnology (IBB) is indicating a NEGATIVE -1.51% DOWNSIDE in Friday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is indicating a NEGATIVE -0.69% DOWNSIDE in Friday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Friday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a NEGATIVE -1.3% DOWNSIDE in Friday’s pre-open

Henry’omics:

As a sector “tracker”, I’ve been skeptical of the multiple declines followed by steep inclines followed by drastic degeneration.

At around 7 a.m. ET, Dow futures implied a drop of more than 300 points at the open on Friday; while, the S&P 500 and Nasdaq 100 futures also pointed to steep losses. The S&P 500 was set to open more than 9% below its 52-week high, a 10% decline would mean it is officially in correction territory.

WATCH OUT - even the curtain on the indexes is falling ...

From Thursday’s night’s newsletter: “remember the myth of Icarus re the current steep incline. Don’t get too lathered-up over today’s incline as I had stated, “The downside influence is not over.”

The iShares NASDAQ Biotechnology (IBB): a week’s history lesson; for a five session aggregate of -8.11% after 4 negative sessions out of 5!

Review the range of the 37 upside from +0.62% (BCLI) to or +17.68% (FATE) while the 7 downside ranges from -0.46% (AGTC) to -3.79% (OSIR) with a 1 flat close (RENE.L).

Interesting stat: Volume INCREASED … look at the depth – 20 out of 37 of the upside had higher (than the 3 month average) volume while 2 of the downside experienced greater volume (than the 3 month average) out of 7.

In 19 sessions in October – there were 15 negative closes and 4 positive closes;
In 19 sessions in September – there were 10 negative closes and 9 positive close;
In 21 August sessions – 6 had negative and 15 had positive closes

Companies in my headlights – It’s your decision; I provide an idea and context:

CRISPR Therapeutics (CRSP) closed up +$1.32 to $33.13 after Wednesday’s -$3.21 to $31.81 after Tuesday’s $35.02, Monday’s $36.47 and last Friday’s $36.04. The aftermarket indication is a negative -$1.13 or -3.41% - BUY to SELL;

BioLife Solutions (BLFS) closed up again +$0.61 to $13.52 with 132.8 k shares traded <3 month average = 310.1 K shares traded> after Wednesday’s +$0.43 to $12.91 with 179.6 K shares traded after Tuesday’s -$0.20 to $12.48 with 196.7 K shares traded after Monday’s $12.68, last Friday’s $12.41. BLFS has a 52 week upside of $83.77% and a positive +$0.18 or +1.36% aftermarket indications –BUY to SELL;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.